Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Patent
1990-06-01
1994-01-25
Lee, Lester L.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
530324, 530325, 530326, 530327, 530328, 530329, 5303871, A61K 3702, C07K 708, C07K 710
Patent
active
052816990
ABSTRACT:
Membrane anchoring peptides which are part of the heavy chain of an associated immunoglobulin (IgM, IgD, IgA, IgE, or IgG), span the cell membrane lipid bilayer of B cells thereby affixing the associated immunoglobulin to the cell membrane surface. The extracellular segments of these peptides are unique for different isotypes, but tend to be very similar among different subclasses of a particular isotype. The extracellular segments form in whole or in part an epitope unique to the B cells which produce each isotype. These membrane-bound immunoglobulin isotype-specific ("migis") extracellular epitopes are not present on the secreted, soluble form of the immunoglobulins, which are not bound to the cell surface by the membrane anchoring peptides. The antibodies of the invention (and other related products) bind the extracellular migis epitopes. Tumorous B cells which produce particular isotypes, whether associated with B cell lymphoma and B cell leukemia, can be destroyed when they are bound by such an antibody (or by a derivative product of such an antibody), by any of a number of well-known mechanisms.
REFERENCES:
Ishida, N. et al., EMBO Journal, 1(9):1117-1123, 1982.
Cheng, H. et al., Nature, 296:410-415, Apr. 1982.
Tyler, B. et al., Proc. Natl. Acad. Sci., 79:2008-2012, Mar. 1982.
Rogers, J., Cell, 26:19-27, Oct. 1981.
Honjo, et al., Cell, 18:559-568, 1979.
Manning, D. D., "Heavy Chain Isotype Suppression: A Review of the Immunosuppressive Effects of Heterologous Anti-Ig Heavy Chain Antisera" J. Reticulo. Soc. 18:63-86. (1975).
Manning, D. D. et al. "Suppression of Reaginic Antibody (IgE) Formation in Mice by Treatment with Anti-.mu. or Anti-.sigma. Antiserum" J. Exp. Med. 144:288-293 (1976).
Bazin, H. et al. "Differential Effect of Neonatal Injections of Anti-.mu. Antibodies on the Synthesis of IgM, IgE, IgA, IgG1, IgG2a, IgG26 and IgG2c Immunoglobulin Classes" J. Immunol. 121:2038-2087 (1978).
Tahghi-Kilani, R. et al. "The Role of Humoral Immunity in Cryptosporidium spp. Infection Studies with B Cell-Depleted Mice" J. Immunol. 145:1571-1576 (1990).
Word et al. "The Murine Immunoglobulin .alpha. Gene Expresses Multiple Transcripts from a Unique Membrane Exon" (particularly; p. 895, 2nd column) EMBO Journal 2:887-898 (1983).
Lee Lester L.
Mirabel Eric P.
Tanox Biosystems, Inc.
LandOfFree
Treating B cell lymphoma or leukemia by targeting specific epito does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating B cell lymphoma or leukemia by targeting specific epito, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating B cell lymphoma or leukemia by targeting specific epito will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-728761